What is the current stock price of Novavax, Inc. (NVAX)?

As of the latest market data, Novavax, Inc. (NVAX) is trading at $11.09. The stock has seen a gain of 6.02% today.

Does Novavax, Inc. (NVAX) pay a dividend?

Based on current data, Novavax, Inc. does not have a confirmed active dividend policy.

What is the market cap of Novavax, Inc.?

The current market capitalization of Novavax, Inc. (NVAX) is approximately unavailable.

NVAX

Novavax, Inc.·Healthcare

11.09

6.023%(+0.63)

Close Price

11.24

1.353%(+0.15)

After Hours

Last Updated: — ET

52W L: $6.1352W H: $11.97

NVAX NEWS

zacks.com

1d ago

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

seekingalpha.com

May 13

Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

fool.com

May 13

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.

zacks.com

May 12

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

247wallst.com

May 11

Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday's close of $54.35.

benzinga.com

May 11

Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb

Moderna Inc. (NASDAQ:MRNA) and Novavax Inc. (NASDAQ:NVAX) shares moved higher Monday as traders piled back into vaccine names following renewed concerns over a hantavirus outbreak tied to the MV Hondius cruise ship.

Company Profile

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sector

Healthcare

Industry

Biotechnology

Employees

952

IPO Date

1995-12-05

Beta

2.37

Websitewww.novavax.com↗